

upper and lower threshold density ranges were adjusted to encompass and match the immunoreactivity (IR) to provide an image with immunoreactive material appearing in black pixels, and non-immunoreactive material as white pixels. A standardized rectangle was positioned over the superficial laminae of the contralateral dorsal horn of the spinal cord area from nerve-ligated mice. The area and density of pixels within the threshold value representing IR were calculated and the integrated density was the product of the area and density. The same box was then 'dragged' to the corresponding position on the superficial laminae of the ipsilateral dorsal horn of the spinal cord area from nerve-ligated mice and the integrated density of pixels within the same threshold was again calculated.

Confocal Ca²⁺ imaging

Tissue processing

Primary spinal cultured neurons were grown as follows: spinal cord was obtained from newborn ICR mice (Tokyo Laboratory Animals Science), minced, and treated with papain (9 U/mL, Worthington Biochemical, Lakewood, NJ, USA) dissolved in PBS solution containing 0.02% L-cysteine monohydrate (Sigma-Aldrich, St Louis, MO, USA), 0.5% glucose and 0.02% bovine serum albumin (Wako Pure Chemical, Osaka, Japan). After enzyme treatment at 37°C for 15 min, cells were seeded on poly-L-lysine (Sigma-Aldrich) with fibronectin (10 µg/mL; Sigma-Aldrich)-coated glass coverslips with a silicon rubber well (Flexiperm[®], Heraeus Biotechnology, Hanau, Germany) at a density of 3×10^6 cells/cm². The cells were maintained for 7 days in Dulbecco's modified Eagle's medium (Invitrogen, Grand Island, NY, USA) supplemented with 10% precolostrum newborn calf serum (Invitrogen), 10 U/mL penicillin and 10 µg/mL streptomycin in a humidified atmosphere of 95% air and 5% CO₂ at 37°C.

Cells were loaded with 10 µM fluo-3AM (Wako Pure Chemical) for 90 min at room temperature. After a further 20–30 min of de-esterification with the acetoxymethyl ester, the coverslips were mounted on a microscope equipped with a confocal Ca²⁺ imaging system (Radiance 2000, Bio-Rad, Richmond, CA, USA). Fluo-3AM was excited with the 488-nm line of an argon-ion laser and the emitted fluorescence was collected at wavelengths >515 nm. To compensate for the uneven distribution of fluo-3AM, self-ratios were calculated ($R_s = F/F_0$).

BDNF 1 ng/mL was perfused for 40 s at a rate of 4–5 mL/min at room temperature in cultured spinal neurons followed by superfusion of balanced salt saline (BSS, pH 7.4) containing 150 mM NaCl, 5.0 mM KCl, 1.8 mM CaCl₂, 1.2 mM MgCl₂, 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid and 10 mM D-glucose. K-252a (15 and 150 nM) or Ro-32-0432 (1 and 10 µM) was pre-treated in cultured spinal neurons 10 min prior to BDNF application at room temperature.

Drugs

The drugs used in the present study were TrkB/Fc (R & D Systems), BDNF (R & D Systems), selective PKC inhibitor Ro-32-0432 (Calbiochem-Novabiochem) and K-252a (Calbiochem-Novabiochem). TrkB/Fc and BDNF were dissolved in sterile PBS and 0.9% sterile physiological saline, respectively. Ro-32-0432 and K-252a were dissolved in 0.9% sterile physiological saline containing 3% dimethylsulfoxide (DMSO). In confocal Ca²⁺

imaging assay, Ro-32-0432 and K-252a were dissolved in BSS containing 0.12 and 0.0018% DMSO, respectively.

Statistical analysis

All data are presented as the mean ± SEM. The statistical significance of differences between groups was assessed with repeated measures analysis of variance (ANOVA) and one-way ANOVA followed by the Bonferroni–Dunn multiple comparison test or Student's *t*-test.

Results

Effect of repeated i.t. injection of TrkB/Fc on thermal hyperalgesia and tactile allodynia induced by sciatic nerve ligation in mice

Partial ligation of the sciatic nerve caused a marked decrease in the latency of paw withdrawal after the thermal stimulus only on the ipsilateral side in nerve-ligated ICR mice (vs. PBS–sham group, $F_{1,16} = 32.384$, $p < 0.001$, Fig. 1a). In contrast, paw withdrawal latencies induced by a thermal stimulus on the contralateral side in nerve-ligated mice and on both sides in sham-operated mice were not changed (Fig. 1b). The thermal hyperalgesia observed on the ipsilateral side in nerve-ligated mice was markedly reversed by repeated i.t. injection of TrkB/Fc (10 ng/mouse) just before the ligation and once a day for 7 consecutive days after the nerve ligation (vs. PBS–ligation group, $F_{1,21} = 17.76$, $p < 0.001$, Fig. 1a).

The mice with sciatic nerve ligation also revealed a marked increase in the paw withdrawal response to the tactile stimulus only on the ipsilateral side in nerve-ligated mice (vs. PBS–sham group, $F_{1,16} = 40.082$, $p < 0.001$, Fig. 2a; vs. PBS–sham group, $F_{1,16} = 23.323$, $p < 0.001$, Fig. 2c). The contralateral side of nerve-ligated mice and both sides of sham-operated mice did not show any responses to the tactile stimulus (Figs 2b and d). Under these conditions, repeated i.t. injection of TrkB/Fc (10 ng/mouse) markedly suppressed the increase in paw withdrawal response to the innocuous tactile stimulus induced by nerve ligation in mice (vs. PBS–ligation group, $F_{1,15} = 12.261$, $p < 0.001$, Fig. 2a; vs. PBS–ligation group, $F_{1,16} = 10.241$, $p < 0.001$, Fig. 2c).

Repeated i.t. injection of TrkB/Fc at doses of which used in the present study failed to affect thermal and tactile threshold on the contralateral side in nerve-ligated mice and on both sides in sham-operated mice (Figs 1 and 2).

Genotyping and general behaviour in BDNF (+/–) knockout mice

The genotype of offspring from the BDNF (+/–) knockout mice was confirmed by PCR analyses using DNA extracted from the tail. Mice having the targeted deficient allele and the wild-type allele revealed a single band of 340 bp (lanes 2 and 4) and 275 bp (lanes 1 and 3), respectively. As shown in Fig. 3, BDNF (+/–) knockout mouse yielded both two




Fig. 1 Effect of repeated i.t. injection of a TrkB receptor chimera protein (TrkB/Fc) on paw withdrawal latency to the thermal stimulus in the ipsilateral (a) and contralateral (b) sides of sham-operated or nerve-ligated mice. Groups of mice were repeatedly i.t. treated with TrkB/Fc (10 ng/mouse) or PBS 1 h prior to surgery (day 0) and once a day for 7 consecutive days after surgery. Each point represents the mean \pm SEM of 8–13 mice. * $p < 0.05$ and *** $p < 0.001$ versus PBS-sham group, ## $p < 0.01$ and ### $p < 0.001$ versus PBS-ligation group.

amplification products (lanes 1 and 2). In contrast, wild-type mouse showed a single amplification product (lanes 3 and 4).

There were no significant differences between BDNF (+/–) knockout and its wild-type mice in body weight [wild-type: 29.0 ± 1.0 g, BDNF (+/–) knockout: 28.7 ± 0.5 g], body temperature [wild-type: $36.6 \pm 0.2^\circ\text{C}$, BDNF (+/–) knockout: $36.7 \pm 0.1^\circ\text{C}$], basal hot-plate latency [wild-type: 13.9 ± 0.6 s, BDNF (+/–) knockout: 13.0 ± 0.8 s], basal tail-flick latency [wild-type: 2.7 ± 0.1 s, BDNF (+/–) knockout: 2.8 ± 0.1 s] and the latency until fall-off from the rota-rod [wild-type: 55 ± 2.9 s, BDNF (+/–) knockout: 48 ± 9.0 s].

Changes in thermal and tactile thresholds induced by sciatic nerve ligation in BDNF (+/–) knockout mice

Baseline latency of paw withdrawal to the thermal stimulus to the plantar surface of BDNF (+/–) knockout mice did not differ from that of wild-type mice [right side, wild-type:




Fig. 2 Effect of repeated i.t. injection of TrkB/Fc on paw withdrawal responses to the tactile stimulus in the ipsilateral (a, c) and contralateral (b, d) sides of sham-operated or nerve-ligated mice. Groups of mice were repeatedly i.t. treated with TrkB/Fc (10 ng/mouse) or PBS 1 h prior to surgery (day 0) and once a day for 8 consecutive days after surgery. Tactile stimulus was performed by two different bending forces [0.02 g (a, b) and 0.16 g (c, d)] of filaments. Each point represents the mean \pm SEM of 5–7 mice. *** $p < 0.001$ versus PBS-sham group, # $p < 0.05$, ## $p < 0.01$ and ### $p < 0.001$ versus PBS-ligation group.

10.1 ± 0.4 s, BDNF (+/–) knockout: 9.3 ± 0.3 s; left side, wild-type: 9.6 ± 0.4 s, BDNF (+/–) knockout: 9.1 ± 0.3 s]. In addition, the baseline paw withdrawal response after the tactile stimulus to the plantar surface of BDNF (+/–) knockout mice did not differ from that of wild-type mice [right side, wild-type: 10.1 ± 0.4 s, BDNF (+/–) knockout: 9.3 ± 0.3 s; left side, wild-type: 9.6 ± 0.4 s, BDNF (+/–) knockout: 9.1 ± 0.3 s].

In wild-type mice, either the thermal or tactile threshold observed on the ipsilateral side was markedly decreased by nerve ligation (vs. wild-type-sham group, $F_{1,16} = 23.755$, $p < 0.001$, Fig. 4a; vs. wild-type-sham group, $F_{1,8} = 4.356$, $p < 0.01$, Fig. 5a). In contrast, either the thermal or tactile threshold on the contralateral side of nerve-ligated wild-type mice and on both sides of sham-operated wild-type mice was not changed (Figs 4b and 5b).

Under these conditions, either the decreased thermal or tactile threshold on the ipsilateral side in BDNF (+/–) knockout mice with nerve ligation was significantly suppressed compared with those observed in wild-type mice (vs. the wild-type-ligation group, $F_{1,18} = 5.781$, $p < 0.001$, Fig. 4a and Fig. 5a). In BDNF (+/–) knockout mice, the paw withdrawal response to either thermal or tactile stimulus on the contralateral side in the nerve-ligated group and on both sides in the sham-operated group was not altered (Figs 4b and 5b).




Fig. 3 Representative PCR for BDNF using DNA extracted from the tail of either wild-type or BDNF (+/-) knockout mouse. Mice having the targeted deficient allele and the wild-type allele revealed a single band of 340 bp (lanes 2 and 4) and 275 bp (lanes 1 and 3), respectively (arrows). BDNF (+/-) knockout mouse yielded both amplification products (lanes 1 and 2). In contrast, wild-type mouse showed a single amplification product (lanes 3 and 4).

Changes in BDNF-like IR by sciatic nerve ligation in the superficial dorsal horn of the mouse spinal cord

The BDNF-like IR was detected on the superficial laminae of the contralateral side of the L5 lumbar spinal dorsal horn of nerve-ligated mice (Fig. 6a). At 7 days after sciatic nerve ligation, BDNF-like IR on the superficial laminae of the ipsilateral side of the L5 lumbar spinal dorsal horn was significantly increased compared with that of the contralateral side ($p < 0.001$, Figs 6b and c).

Changes in thermal and tactile thresholds following an exogenous single i.t. treatment with BDNF in normal mice

We next investigated whether an exogenous i.t. treatment with BDNF could cause a hyperalgesic or allodynic response in normal mice. A single i.t. injection of BDNF (50 ng/mouse) produced a marked thermal hyperalgesia in normal mice after the injection, and this effect lasted for 5 days after the injection (vs. vehicle-saline group, $F_{1,13} = 10.493$, $p < 0.001$, Fig. 7a). The long-lasting thermal hyperalgesia caused by an exogenous single i.t. injection of BDNF was abolished by i.t. pre-treatment with a Trk-dependent tyrosine kinase inhibitor K-252a (1 nmol/mouse; vs. vehicle-BDNF group, $F_{1,12} = 10.178$, $p < 0.001$, Fig. 7a). In addition, the mice treated i.t. with BDNF (50 ng/mouse) revealed a marked and long-lasting tactile allodynia (vs. vehicle-saline




Fig. 4 Changes in paw withdrawal latencies to the thermal stimulus induced by nerve ligation on the ipsilateral (a) and contralateral (b) sides in wild-type and BDNF (+/-) knockout (KO) mice. Each point represents the mean \pm SEM of 7–10 mice. ** $p < 0.01$ and *** $p < 0.001$ versus wild-type-sham group, # $p < 0.05$, ### $p < 0.01$ and ### $p < 0.001$ versus wild-type-ligation group.

group, $F_{1,14} = 4.662$, $p < 0.001$, Fig. 7b). The persistent tactile allodynia caused by an exogenous single i.t. injection of BDNF was also abolished by i.t. pre-treatment with K-252a (1 nmol/mouse; vs. vehicle-BDNF group, $F_{1,14} = 3.483$, $p < 0.01$, Fig. 7b).

An i.t. pre-treatment with a selective PKC inhibitor Ro-32-0432 (1 nmol/mouse) also completely suppressed thermal hyperalgesia and tactile allodynia induced by an exogenous single i.t. injection of BDNF (50 ng/mouse; vs. vehicle-BDNF group, $F_{1,12} = 5.51$, $p < 0.001$, Fig. 7a; vs. vehicle-BDNF group, $F_{1,13} = 2.64$, $p < 0.05$, Fig. 7b).

Effect of PKC inhibitor on the BDNF-induced Ca^{2+} responses in cultured mouse spinal neurons

To clarify whether PKC is a downstream effector for a BDNF-mediated signalling event, we next investigated the effect of PKC inhibitor on the BDNF-induced Ca^{2+} responses in cultured mouse spinal neurons. Application of




Fig. 5 Changes in paw withdrawal responses to the tactile stimulus induced by nerve ligation on the ipsilateral (a) and contralateral (b) sides in wild-type and BDNF (+/-) knockout (KO) mice. Tactile stimulus was performed by 0.02 g of von Frey filament. Each point represents the mean \pm SEM of 3–6 mice. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$ versus wild-type–sham group, # $p < 0.05$ and ### $p < 0.001$ versus wild-type–ligation group.

BDNF (1 ng/mL) into the cultured spinal neurons produced a transient increase in the intracellular Ca^{2+} levels (Fig. 8a). The Ca^{2+} response induced by BDNF (1 ng/mL) was abolished by pre-treatment with K-252a in a concentration-dependent manner [15 and 150 nM; vs. BDNF-treated cells, $p < 0.01$ (15 nM) and $p < 0.001$ (150 nM), Fig. 8bi and c]. In addition, pre-treatment with Ro-32-0432 (1 and 10 μ M) exhibited a concentration dependent suppression of the increased intracellular Ca^{2+} concentration induced by BDNF [1 ng/mL; vs. BDNF-treated cells, $p < 0.001$, Figs 8bii and c].

Discussion

We previously reported that the sciatic nerve ligation-induced thermal hyperalgesia was completely reversed by repeated i.t. treatment with specific antibodies to BDNF and the full-length TrkB receptor, and the inhibitor of Trk-dependent tyrosine kinase K-252a in mice (Yajima *et al.* 2002). In the




Fig. 6 Photomicrographs of immunofluorescent staining of BDNF on the superficial layers of the contralateral (a) or ipsilateral (b) spinal dorsal horn of ICR mice at 7 days after nerve ligation. (c) The density of BDNF-like IR of each side of the spinal cord slice was measured using an NIH image. The level of BDNF on the superficial dorsal horn of the ipsilateral spinal cord in nerve-ligated mice is expressed as a per cent increase (mean \pm SEM) with respect to that in the contralateral side. BDNF-like IR observed on the superficial laminae of the ipsilateral dorsal horn (b) was significantly increased compared with that of the contralateral side (a). *** $p < 0.001$ versus contralateral side. Three independent sets of experiment were performed in this study. Scale bars = 50 μ m.

present study, we further investigated the substantial role of the spinal BDNF/TrkB receptor pathway in the development of the neuropathic pain-like state in mice using TrkB receptor chimera protein (TrkB/Fc), which sequesters endogenous BDNF, and BDNF (+/-) mutant mice.

Thermal hyperalgesia and tactile allodynia induced by sciatic nerve ligation were markedly suppressed by repeated i.t. treatment with TrkB/Fc. The TrkB/Fc used in the present study is bivalent homodimers that contain the extracellular ligand-binding domain of a given TrkB receptor followed by the hinge and Fc γ region of human IgG1 (Binder *et al.* 1999). This compound acts as TrkB receptor body to sequester endogenous BDNF and neurotrophin-4/5 (NT-4/5), which also preferentially binds to TrkB. It has been reported that TrkB/Fc specifically abolished Trk phosphorylation induced by BDNF in primary cortical cultures (Binder *et al.* 1999), suggesting that this molecule is a highly potent and specific inhibitor for endogenous BDNF and NT-4/5. Considering these findings, the present data indicate the possibility that the release of BDNF and NT-4/5 within the spinal cord by nerve ligation may be implicated in




Fig. 7 Effect of a single i.t. injection of BDNF on paw withdrawal responses to the thermal (a, c) and tactile (b, d) stimulus in normal mice. Tactile stimulus was performed using 0.02 g bending force of filament. Groups of mice were pre-treated i.t. with either a Trk-dependent tyrosine kinase inhibitor K-252a (1 nmol/mouse) or a selective PKC inhibitor Ro-32-0432 (RO; 1 nmol/mouse) 30 min before a single i.t. injection of BDNF (50 ng/mouse; a, b) or saline (c, d). Each point represents the mean \pm SEM of 6–9 mice. * p < 0.05, ** p < 0.01 and *** p < 0.001 versus day 0 (vehicle–BDNF group), † p < 0.05, †† p < 0.01 and ††† p < 0.001 vehicle–BDNF group versus K-252a–BDNF group, # p < 0.05 and ### p < 0.001 vehicle–BDNF group versus RO–BDNF group.

the development of a neuropathic pain-like state in mice. However, we already found that repeated i.t. injection of a specific antibody to NT-4, unlike BDNF, failed to suppress thermal hyperalgesia caused by sciatic nerve ligation in mice (Yajima *et al.* 2002). In addition, there are no differences in the spinal cord reflex properties between NT-4-deficient and its wild-type mice (Heppenstall and Lewin 2001). Taken together, these findings indicate that the BDNF released within the spinal cord by sciatic nerve injury may trigger the inducing of the development of a neuropathic pain-like state in mice.

Then, the direct approach using BDNF (+/–) knockout mice was performed to investigate whether a mutation of the BDNF gene could influence the development of a neuropathic pain-like state induced by sciatic nerve ligation in




Fig. 8 Effect of K-252a or Ro-32-0432 on the BDNF-induced increase in intracellular Ca²⁺ concentration in cultured spinal neurons. (a, bi, bii) Sequential images of increase in intracellular Ca²⁺ concentration induced by BDNF (1 ng/mL) in cultured spinal neurons. BDNF at 1 ng/mL was applied by superfusion for 40 s. K-252a (15 and 150 nM) or Ro-32-0432 (1 and 10 μ M) was pre-treated in cultured spinal neurons 10 min prior to BDNF (1 ng/mL) application. (c) Amplitude of the BDNF-induced increases in intracellular Ca²⁺ concentration in spinal neurons. K-252a (15 and 150 nM) or Ro-32-0432 (1 and 10 μ M) was pre-treated in cultured spinal neurons 10 min prior to BDNF (1 ng/mL) application. Data represent the mean \pm SEM of 54–126 cells from three separated observations. ## p < 0.01 and ### p < 0.001 versus BDNF-treated cells.

mice. As shown in Fig. 3, there were no differences in some physiological and behavioural responses, including nociceptive properties and motor coordination, between BDNF (+/–) knockout and its wild-type mice. Under these conditions, it should be noted that BDNF (+/–) knockout mice revealed a significant suppression of nerve ligation-induced thermal hyperalgesia and tactile allodynia compared with those observed in wild-type mice. Moreover, exogenous treatment with BDNF increases the excitability of

nociceptive inputs in the spinal neurons (Kerr *et al.* 1999; Thompson *et al.* 1999; Groth and Aanonsen 2002), while the spinal reflex elicited by stimulation of primary afferents is reduced in BDNF-deficient mice (Heppenstall and Lewin 2001). Consistent with these observations, we demonstrated here that an exogenous single i.t. injection of BDNF produced a long-lasting thermal hyperalgesia and tactile allodynia in normal mice. These responses were abolished by i.t. pre-treatment with a Trk-dependent tyrosine kinase inhibitor K-252a (Doherty and Walsh 1989). These findings provide further evidence for the critical role of BDNF within the spinal cord in neuropathic pain processing.

In terms of the distribution of BDNF-like IR (Ha *et al.* 2001; Groth and Aanonsen 2002), we confirmed that BDNF-like IR was detected on the superficial laminae of the dorsal horn of the spinal cord. In our preliminary study, the BDNF-like IR was clearly overlapped with a specific neuronal marker microtubule-associated protein 2a/b (MAP2a/b), but not a specific astroglial marker glial fibrillary acidic protein (GFAP; unpublished observation), indicating that BDNF within the spinal cord may be predominantly located in neurons. Under these conditions, we next investigated whether sciatic nerve ligation could affect BDNF-like IR on the superficial dorsal horn of the spinal cord. Here, we showed that sciatic nerve ligation produced a marked increase in BDNF-like IR on the superficial layers of the ipsilateral side of the spinal cord compared with that observed in the contralateral side of nerve-ligated mice. It is well documented that BDNF mRNA expression is mostly detected in small- to medium-size DRG cells, and the synthesized BDNF in the DRGs is anterogradely transported to the spinal cord through the primary afferents (Zhou *et al.* 1999; Obata *et al.* 2003). On the contrary, there is no expression of BDNF mRNA throughout the spinal cord (Conner *et al.* 1997; Heppenstall and Lewin 2001) and BDNF-like IR was not found in postsynaptic neurons (Luo *et al.* 2001), indicating that the distributed BDNF in the spinal cord may be derived from primary afferent neurons, but not from postsynaptic cells in the spinal cord. Recently, it has been shown that BDNF synthesis is increased in the ipsilateral DRGs (Shen *et al.* 1999; Zhou *et al.* 1999) and the anterogradely transported BDNF is substantially enhanced by sciatic nerve lesion (Tonra *et al.* 1998). It is noteworthy that there is a close association in the time course of the development and disappearance of behavioural signs of neuropathic pain with changes in BDNF levels in the lumbar spinal dorsal horn (Miletic and Miletic 2002). Moreover, DRG-derived neurotrophins, including BDNF, trigger allodynia after spinal nerve injury in rats (Zhou *et al.* 2000). These findings provide further explanation for the implication of spinally released BDNF in the development of a neuropathic pain-like state in mice.

Several lines of evidence have demonstrated that the activation of PKC in the spinal cord plays a critical role in the

sensitization of spinal dorsal horn (Coderre 1992; Munro *et al.* 1994; Lin 1996). There is substantial evidence supporting a role for PKC expressed in dorsal horn neurons in regulating pain hypersensitivity in a number of differential neuropathic pain models (Mao *et al.* 1995; Malmberg *et al.* 1997; Hua *et al.* 1999; Ohsawa *et al.* 2000, 2001). Consistent with previous reports, we found that mice with nerve ligation showed a spinal PKC-dependent neuropathic pain-like behaviour (Ohsawa *et al.* 2000; Yajima *et al.* 2003). In addition, it is of interest to note that direct activation of spinal PKC by a single i.t. injection of the specific PKC activator phorbol 12,13-dibutyrate caused a persistent thermal hyperalgesia in normal mice (Narita *et al.* 2004; Oe *et al.* 2004). It has been well documented that autophosphorylated TrkB receptor by BDNF leads to the enhancement of phospholipase C (PLC) γ_1 activity through the src homology 2 (SH2) domain of PLC γ_1 (Rhee and Bae 1997; Sekiya *et al.* 1999; Yuen and Mobley 1999), leading to facilitating the activation of PKC cascades and an increase in the intracellular Ca²⁺ levels (Zirrgiebel *et al.* 1995). Our recent findings showed that the membrane-bound TrkB receptor was clearly increased in the ipsilateral side of spinal cord of nerve-ligated mice (Narita *et al.* 2000; Yajima *et al.* 2002). It should be mentioned that the increase in the level of membrane-located TrkB receptor on the ipsilateral spinal cord in nerve-ligated mice was paralleled with a time course of the increase in the membrane-bound PKC γ isoform on the ipsilateral spinal cord in nerve-ligated mice (Narita *et al.* 2000). Although there is substantial evidence supporting the idea of the importance of spinal PKC in the development of a neuropathic pain-like state, little is known about the direct interaction between BDNF and PKC under a chronic pain-like state. In the present study, we demonstrated here that single i.t. administration of BDNF-induced long-lasting thermal hyperalgesia and tactile allodynia were completely reversed by i.t. pre-treatment with a selective PKC inhibitor Ro-32-0432. Supporting these findings, we found here for the first time that application of BDNF in primary spinal neurons increased the intracellular Ca²⁺ concentrations, and this effect was abolished by pre-treatment with Ro-32-0432. In addition, pre-treatment with K-252a also abolished both the BDNF-induced pain-like state and Ca²⁺ responses in the cultured spinal neurons, indicating that the TrkB receptor/PKC-mediated signalling pathway within the spinal cord may be involved in this event. Collectively, these findings strongly support the idea that BDNF activates PKC through the activated TrkB receptor on the spinal dorsal horn neurons, which may in turn cause the development of a neuropathic pain-like state.

In conclusion, present data provided further evidence that the BDNF/TrkB receptor-mediated signalling pathway within the spinal cord is involved in the development of a neuropathic pain-like state induced by sciatic nerve ligation in mice. Considering these observations, a hypothesis may be

advanced that the BDNF released within the spinal cord by nerve injury can eventually activate PKC through the TrkB receptor located on the spinal dorsal horn neurons, resulting in the development of a neuropathic pain-like state.

Acknowledgements

This work was supported by a Research Grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We wish thank to Mr Toshiro Kase and Ms Fumi Takabayashi for their expert technical assistance.

References

- Back S. K., Kim J. S., Hong S. K. and Na H. S. (2003) Ascending pathway for mechanical allodynia in a rat model of neuropathic pain. *Neuroreport* **14**, 1623–1626.
- Binder D. K., Routhort M. J., Ryan T. E., Yancopoulos G. D. and McNamara J. O. (1999) Selective inhibition of kindling development by intraventricular administration of TrkB receptor body. *J. Neurosci.* **19**, 1424–1436.
- Coderre T. J. (1992) Contribution of protein kinase C to central sensitization and persistent pain following tissue injury. *Neurosci. Lett.* **140**, 181–184.
- Conner J. M., Lauterborn J. C., Yan Q., Gall C. M. and Varon S. (1997) Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. *J. Neurosci.* **17**, 2295–2313.
- Doherty P. and Walsh F. S. (1989) K-252a specifically inhibits the survival and morphological differentiation of NGF-dependent neurons in primary cultures of human dorsal root ganglia. *Neurosci. Lett.* **96**, 1–6.
- Erfors P., Lee K.-F. and Jaenisch R. (1994) Mice lacking brain-derived neurotrophic factor develop with sensory deficits. *Nature* **368**, 147–150.
- Groth R. and Aanonsen L. (2002) Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense, directed against either BDNF or TrkB, prevent inflammation-induced hyperalgesia. *Pain* **100**, 171–181.
- Ha S. O., Kim J. K., Hong H. S., Kim D. S. and Cho H. J. (2001) Expression of brain-derived neurotrophic factor in rat dorsal root ganglia, spinal cord and gracile nuclei in experimental models of neuropathic pain. *Neuroscience* **2**, 301–309.
- Heppenstall P. A. and Lewin G. R. (2001) BDNF but not NT-4 is required for normal flexion reflex plasticity and function. *Proc. Natl Acad. Sci. USA* **98**, 107–112.
- Hua X.-Y., Chen P. and Yaksh T. L. (1999) Inhibition of spinal protein kinase C reduces nerve injury-induced tactile allodynia in neuropathic rats. *Neurosci. Lett.* **276**, 99–102.
- Hylden J. L. K. and Wilcox G. L. (1980) Intrathecal morphine in mice: a new technique. *Eur. J. Pharmacol.* **67**, 313–316.
- Ji R.-R. and Woolf C. J. (2001) Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. *Neurobiol. Dis.* **8**, 1–10.
- Kafiz K. W., Rose C. R., Thoenen H. and Konnerth A. (1999) Neurotrophin-evoked rapid excitation through TrkB receptors. *Nature* **401**, 918–921.
- Kerr B. J., Bradbury E. J., Bennett D. L. H., Trivedi P. M., Dassan P., French J., Shelton D. B., McMahon S. B. and Thompson S. W. N. (1999) Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. *J. Neurosci.* **19**, 5138–5148.
- Lever I. J., Bradbury E. J., Cunningham J. R., Adelson D. W., Jones M. G., McMahon S. B., Marvizon J. C. G. and Malcangio M. (2001) Brain-derived neurotrophic factor is released in the dorsal horn by distinctive patterns of afferent fiber stimulation. *J. Neurosci.* **21**, 4469–4477.
- Lin Q. (1996) Possible role of protein kinase C in the sensitization of primate spinothalamic tract neurons. *J. Neurosci.* **16**, 3026–3034.
- Luo X. G., Rush R. A. and Zhou X.-F. (2001) Ultrastructural localization of brain-derived neurotrophic factor in rat primary sensory neurons. *Neurosci. Res.* **39**, 377–384.
- Malmberg A. and Basbaum A. I. (1998) Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. *Pain* **76**, 215–222.
- Malmberg A., Chen C., Tonegawa S. and Basbaum A. I. (1997) Preserved acute pain and reduced neuropathic pain in mice lacking PKC γ . *Science* **278**, 279–283.
- Mao J., Price D. D., Phillips L. L., Lu J. and Mayer D. J. (1995) Increases in protein kinase C γ immunoreactivity in the spinal cord dorsal horn of rats with painful mononeuropathy. *Neurosci. Lett.* **198**, 75–78.
- Michael G. J., Averill A., Nitkunan A., Rattray M., Bennett D. L. H., Yan Q. and Priestley J. V. (1997) Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. *J. Neurosci.* **17**, 8476–8490.
- Miletic G. and Miletic V. (2002) Increases in the concentration of brain-derived neurotrophic factor in the lumbar spinal dorsal horn are associated with pain behavior following chronic constriction injury in rats. *Neurosci. Lett.* **319**, 137–140.
- Munro F. E., Fleetwood-Walker S. M. and Mitchell R. (1994) Evidence for a role of protein kinase C in the sustained activation of rat dorsal horn neurons evoked by cutaneous mustard oil application. *Neurosci. Lett.* **170**, 199–202.
- Narita M., Yajima Y., Aoki T., Ozaki S., Narita M., Mizoguchi H., Tseng L. F. and Suzuki T. (2000) Up-regulation of the TrkB receptor in mice injured by the partial ligation of the sciatic nerve. *Eur. J. Pharmacol.* **401**, 187–190.
- Narita M., Imai S., Oe K., Narita M., Kubota C., Yajima Y., Yamazaki M. and Suzuki T. (2004) Induction of c-fos expression in the mouse brain associated with hyperalgesia induced by intrathecal injection of protein kinase C activator. *Brain Res.* **1015**, 181–193.
- Obata K., Yamanaka H., Tachibana T., Fukuoka T., Tokunaga A., Yoshikawa H. and Noguchi K. (2003) Differential activation of extracellular signal-regulated protein kinase in primary afferent neurons regulates brain-derived neurotrophic factor expression after peripheral inflammation and nerve injury. *J. Neurosci.* **23**, 4117–4126.
- Oe K., Narita M., Imai S., Shibasaki M., Kubota C., Kasukawa A., Hamaguchi M., Yajima Y., Yamazaki M. and Suzuki T. (2004) Inhibition of the morphine-induced rewarding effect by direct activation of spinal protein kinase C in mice. *Psychopharmacology* **177**, 55–60.
- Ohsawa M., Narita M., Mizoguchi H., Suzuki T. and Tseng L. F. (2000) Involvement of spinal protein kinase C in thermal hyperalgesia evoked by partial sciatic nerve ligation, but not by inflammation in the mouse. *Eur. J. Pharmacol.* **403**, 81–85.
- Ohsawa M., Narita M., Mizoguchi H., Cheng E. and Tseng L. F. (2001) Reduced hyperalgesia induced by nerve injury, but not by inflammation in mice lacking protein kinase C γ isoform. *Eur. J. Pharmacol.* **429**, 157–160.
- Pezet S., Malcangio M. and McMahon S. B. (2002) BDNF: a neuro-modulator in nociceptive pathways? *Brain Res. Rev.* **40**, 240–249.
- Poo M. M. (2001) Neurotrophins as synaptic modulators. *Nat. Rev.* **2**, 24–32.

- Rhee S. G. and Bae Y. S. (1997) Regulation of phosphoinositide-specific phospholipase C isozymes. *J. Biol. Chem.* **272**, 15 045–15 048.
- Sekiya F., Bae Y. S. and Rhee S. G. (1999) Regulation of phospholipase C isozymes: activation of phospholipase C γ in the absence of tyrosine-phosphorylation. *Chem. Physics Lipids* **98**, 3–11.
- Shen H., Chung J. M. and Chung K. (1999) Expression of neurotrophin mRNAs in the dorsal root ganglion after spinal nerve injury. *Mol. Brain Res.* **64**, 186–192.
- Sun H., Ren K., Zhong C. M., Ossipov M. H., Malan T. P., Lai J. and Porreca F. (2001) Nerve injury-induced tactile allodynia is mediated via ascending spinal dorsal column projections. *Pain* **90**, 105–111.
- Thompson S. W. N., Bennett D. L. H., Kerr B. J., Bradbury E. J. and McMahon S. B. (1999) Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. *Proc. Natl Acad. Sci. USA* **96**, 7714–7718.
- Tonra J. R., Curtis R., Wong V., Cliffer K. D., Park J. S., Timmes A., Nguyen T., Lindsay R. M., Acheson A. and DiStefano P. S. (1998) Axotomy upregulates the anterograde transport and expression of brain-derived neurotrophic factor by sensory neurons. *J. Neurosci.* **18**, 4374–4383.
- Ward N. L. and Hagg T. (2000) BDNF is needed for postnatal maturation of basal forebrain and neostriatum cholinergic neurons *in vivo*. *Exp. Neurol.* **162**, 297–310.
- Yajima Y., Narita M., Narita M., Matsumoto N. and Suzuki T. (2002) Involvement of a spinal brain-derived neurotrophic factor/full-length TrkB pathway in the development of nerve injury-induced thermal hyperalgesia in mice. *Brain Res.* **958**, 338–346.
- Yajima Y., Narita M., Shimamura M., Narita M., Kubota C. and Suzuki T. (2003) Differential involvement of spinal protein kinase C and protein kinase A in neuropathic and inflammatory pain in mice. *Brain Res.* **992**, 288–293.
- Yuen E. C. and Mobley W. C. (1999) Early BDNF, NT-3 and NT-4 signaling events. *Exp. Neurol.* **159**, 297–308.
- Zhou X. F. and Rush R. A. (1996) Endogenous brain-derived neurotrophic factor is anterogradely transported in primary sensory neurons. *Neuroscience* **74**, 945–951.
- Zhou X. F., Chie E. T., Deng Y. S., Zhong J. H., Xue Q., Rush R. A. and Xian C. J. (1999) Injured primary sensory neurons switch phenotype for brain-derived neurotrophic factor in the rat. *Neuroscience* **92**, 841–853.
- Zhou X. F., Deng Y. S., Xian C. J. and Zhong J. H. (2000) Neurotrophins from dorsal root ganglia trigger allodynia after spinal nerve injury in rats. *Eur. J. Neurosci.* **12**, 100–105.
- Zirrgiebel U., Ohga Y., Carter B., Beminger B., Inagaki N., Thoenen H. and Lindholm D. (1995) Characterization of TrkB receptor-mediated signaling pathways in rat cerebellar granule neurons: involvement of protein kinase C in neuronal survival. *J. Neurochem.* **65**, 2241–2250.



Chronic morphine treatment increases the expression of the neural cell adhesion molecule in the dorsal horn of the mouse spinal cord

Masami Suzuki, Minoru Narita*, Michiko Narita, Keiichi Niikura, Tsutomu Suzuki*

Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan

Received 23 October 2005; received in revised form 28 January 2006; accepted 31 January 2006

Abstract

It is well known that prolonged exposure to morphine results in tolerance to morphine-induced antinociception. In the present study, we found that mice that were tolerant to morphine-induced antinociception exhibited an increase in immunoreactivity for the neural cell adhesion molecule in the dorsal horn of the spinal cord, which was highly overlapped with immunoreactivity for the increased metabotropic glutamate receptor 5 (mGluR5) induced by morphine. These findings support the idea that repeated stimulation of μ -opioid receptors increases the expression of neural cell adhesion molecule and metabotropic glutamate receptor 5. This phenomenon leads to the enhanced excitatory synaptic transmission in the dorsal horn of the spinal cord, and in turn suppresses the morphine-induced antinociception.

© 2006 Elsevier Ireland Ltd. All rights reserved.

Keywords: Morphine; Tolerance; Neural cell adhesion molecule (NCAM); Metabotropic glutamate receptor 5 (mGluR5)

In the central nervous system, neuronal transmission relies on signals transmitted through a vast array of excitatory and inhibitory neuronal synaptic connections. During the formation of synaptic connections, neurons extend their processes to specific locations where they find appropriate targets and form contacts through transcellular adhesive interactions. Contact and synapse formation are commonly thought to occur between an axonal growth cone and dendritic shaft. Initial contact establishment is followed by spatially and temporally controlled changes to form a mature synapse characterized by the specific accumulation of synaptic vesicles and active zone components within the axon, in close apposition to dendritic membrane studded with receptors [10].

The neural cell adhesion molecule (NCAM), a member of the Ig superfamily expressed on the surface of most neural cells, is involved in cell–cell interactions during brain development, synaptic plasticity, and regeneration [13]. It was further determined that NCAM expression regulates both the number of synapses and strength of excita-

tory synaptic connections in a glutamate receptor-dependent manner [4].

Long-term exposure to morphine results in tolerance to opioids-induced antinociception. It has been well established that glutamate receptors are critical for the development and maintenance of opioid tolerance [2,12]. Therefore, the present study was undertaken to determine the effects of repeated exposure to morphine injection on NCAM expression associated with changes in excitatory synaptic connections in the mouse spinal cord.

The present study was conducted in accordance with the Guiding Principles for the Care and Use of Laboratory Animals, Hoshi University, as adopted by the Committee on Animal Research of Hoshi University, which is accredited by the Ministry of Education, Culture, Sports, Science and Technology of Japan. Male ICR mice (Tokyo Laboratory Animals Science Co., Ltd., Tokyo, Japan) were used. Animals were kept in a room with an ambient temperature of 23 ± 1 °C and a 12-h light–dark cycle (lights on 08:00–20:00 h). Food and water were available ad libitum.

The drugs used were morphine hydrochloride (Sankyo Co., Tokyo, Japan).

Intrathecal (i.t.) injection was performed according to the method described by Hylden and Wilcox [5] using a 25 μ L

* Corresponding authors. Tel.: +81 3 5498 5628; fax: +81 3 5498 5831.

E-mail addresses: narita@hoshi.ac.jp (M. Narita), suzuki@hoshi.ac.jp (T. Suzuki).

Hamilton syringe with a 30 1/2-gauge needle. The volume for i.t. injection was 4 μ L per mouse.

To investigate the development of antinociceptive tolerance following repeated treatment with morphine, mice were repeatedly s.c. injected with morphine (10 mg/kg s.c.) or saline (10 mL/kg s.c.) once a day for 7 consecutive days. Twenty-four hours after the last repeated injection, groups of mice were challenged i.t. with morphine (0.0056–10 nmol/mouse). The antinociceptive response was evaluated by the tail-flick test 10 min after morphine injection (Muromachi Kikai Co., Tokyo, Japan). To prevent tissue damage, we established a 10 s cut-off time. Antinociception was calculated as percentage of the maximum possible effect (%MPE) according to the following formula: %MPE = (test latency – pre-drug latency)/(cut-off time – pre-drug latency) \times 100. Antinociceptive response represents as the mean \pm S.E.M. of percentage antinociception. The ED₅₀ value was calculated by GraphPad Prism Programs version 3.0 (GraphPad Software Inc., CA, USA). Statistical analysis was performed using *F*-test.

Groups of mice were repeatedly injected with morphine (10 mg/kg s.c.) and saline (10 mL/kg s.c.) once a day for 7 consecutive days. Twenty-four hours after the last injection, mice were sacrificed by decapitation. Their whole spinal cords were removed quickly and homogenized in ice-cold buffer A containing 20 mM Tris–HCl (pH 7.5), 2 mM EDTA, 0.5 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 25 μ g of leupeptin per mL, 0.1 mg of aprotinin per mL and 0.32 M sucrose. The homogenate was centrifuged at 1000 \times *g* for 10 min and the supernatant was ultracentrifuged at 100,000 \times *g* for 30 min at 4 $^{\circ}$ C. The pellets were washed with buffer B (buffer A without sucrose) and then ultracentrifuged at 100,000 \times *g* for 30 min. The final pellets were retained as the membranous fraction for Western blotting at –80 $^{\circ}$ C until the assay. Total protein concentration in each sample was determined by the Bradford assay [3]. Sample aliquots containing 10–20 μ g total proteins were separated by size on 5–20% SDS–polyacrylamide gradient gel and transferred to nitrocellulose membranes. The membrane was incubated with primary antibody diluted in Tris-buffered saline (TBS) (1:1000 neural cell adhesion molecule (NCAM, Chemicon), 1:30,000 metabotropic glutamate receptor 5 (mGluR5, Upstate)) containing 5% nonfat dried milk. Immunoreactive bands were detected using SuperSignal West Dura chemiluminescent kit (Pierce, Rockford, IL, USA) and quantified using NIH Image. Statistical analyses were performed using Student's *t*-test.

Mice were repeatedly injected with morphine (10 mg/kg s.c.) and saline (10 mL/kg s.c.) once a day for 7 consecutive days. Twenty-four hours after the last injection, mice were deeply anesthetized with sodium pentobarbital (70 mg/kg, i.p.) and prepared for immunostaining as described previously [9]. The L5 lumbar spinal cord segments were cut with a freezing cryostat (Leica CM 1510) at the thickness of 10 μ m and thaw-mounted on poly-L-lysine-coated glass slides. The spinal cord sections were blocked in 10% normal goat serum (NGS) in 0.01 M phosphate-buffered saline (PBS) and incubated with each primary antibodies (1:100 NCAM (Chemicon), 1:3000 mGluR5 (Upstate)) and incubated 48 h at 4 $^{\circ}$ C. The antibody was then




Fig. 1. Development of tolerance to morphine-induced antinociception. Mice were injected repeatedly once a day for 7 consecutive days with saline or morphine 10 mg/kg (s.c.). Twenty-four hours after the last repeated injection, groups of mice were challenged i.t. with morphine (0.0056–10.0 nmol/mouse). The dose–response curve for the antinociceptive effect of morphine in morphine-treated mice (triangle, ED₅₀: 0.36 (0.15–0.87) nmol/mouse, i.t.) was shifted to the right compared to saline-treated mice (square, ED₅₀: 0.05 (0.03–0.08) nmol/mouse, i.t.). Each point represents the mean \pm S.E.M. of 6–16 mice. *p* < 0.001, *F*_{1,52} = 64.3, chronic saline treatment vs. chronic morphine treatment.

rinsed and incubated with each secondary antibodies conjugated with Alexa 564 and Alexa 488. Fluorescence immunolabeling was observed with a light microscope (Olympus BX-80; Olympus, Tokyo, Japan) and photographed with a digital camera (CoolSNAP HQ; Olympus). Digitized images of superficial laminae of the spinal dorsal horn sections were captured at a resolution of 1316 \times 1035 pixels with camera.

To investigate the development of antinociceptive tolerance, mice were repeatedly injected with morphine (10 mg/kg, s.c.) or saline once a day for 7 consecutive days. Repeated s.c. injection of morphine significantly suppressed the spinal antinociceptive effect induced by i.t.-administered morphine (0.0056–10.0 nmol/mouse). The dose–response curve for antinociceptive effect of morphine was clearly shifted to the right following repeated s.c. treatment with morphine, indicating the development of tolerance to morphine-induced spinal antinociception (Fig. 1; *p* < 0.001, *F*_{1,52} = 64.3).

Twenty-four hours after the last repeated injection of morphine, the IRs for mGluR5 and NCAM in the spinal cord were observed by immunohistochemical analysis. In saline-treated mice, the intense NCAM-IR was confined to laminae I–II in the dorsal horn of the spinal cord (Fig. 2A). Furthermore, the most intense mGluR5-IR appeared to be concentrated in inner part of lamina II (lamina III). Interestingly, repeated treatment with morphine produced the increase in both NCAM-IR and mGluR5-IR in the dorsal horn of the spinal cord (Fig. 2B). It should be mentioned that the increased mGluR5-IR by morphine was extended to the outer part of laminae II and III as well as III. Moreover, the red labeling for NCAM-IR and green labeling for mGluR5-IR showed apparent co-localization in the laminae II–III in the spinal cord of morphine-treated mice. In high-magnification image of the lamina III, the neuropil and




Fig. 2. (A and B) Increase in levels of NCAM-IR and mGluR5-IR in the dorsal horn of the spinal cord following repeated treatment with morphine. The increased mGluR5-IR (green) was more apparent co-localization with NCAM-IR (red) in the spinal cord of morphine-treated mice (B), as compared to saline-treated mice (A). (C and D) Quantitative analysis for levels of NCAM (C) and mGluR5 (D) in the mouse spinal cord after repeated morphine treatment. Upper: representative Western blot of NCAM and mGluR5. Lower: changes in immunoreactivities for NCAM and mGluR5 in membranes of spinal cords obtained from saline- or morphine-treated mice. Mice were repeatedly injected with saline or morphine (10 mg/kg, s.c.) once a day for 7 consecutive days. The membrane fraction was prepared at 24 h after the last injection. Each column represents the mean \pm S.E.M. of three independent samples. *** $p < 0.001$ vs. saline-treated mice. Scale bars: 50 μ m. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of the article.)

granular immunolabelings for the NCAM and mGluR5 were observed surrounding neuronal somata. As shown in Fig. 2C and D, Western blots showed that the protein levels of NCAM and mGluR5 in the spinal cord of morphine-treated mice were significantly increased compared to those in saline-treated mice (Fig. 2C: NCAM; $129.0 \pm 1.1\%$ of control, Fig. 2D: mGluR5; $136.9 \pm 2.4\%$ of control, $p < 0.001$).

The key finding in the present study was that repeated *in vivo* treatment with morphine induced a significant increase in the expression of NCAM in the mouse spinal cord, as detected by both immunohistochemical study and Western blots using the specific NCAM antibody, which recognizes at the neural cell surface of glycoproteins. NCAM is expressed by all neural cell types, subserving neuron–neuron and neuron–glia adhesion via homophilic and heterophilic interactions with other adhe-

sion and extracellular matrix molecules. In the present study, double-immunofluorescence analysis revealed that the increased NCAM-IR located in the laminae I–II was highly co-localized with the increased mGluR5-IR in outer part of laminae II and I as well as III following repeated treatment with morphine. It has been reported that mGluR5-IR in the dorsal horn of the spinal cord is mostly observed in the dendritic shafts and cell body of the postsynaptic neurons, but not in astrocytes [18]. In addition, several lines of evidence demonstrate that the selective mGluR5 antagonist prevents the development of tolerance to morphine-induced antinociception [7,8,11]. Furthermore, it is considerable that the relative level of postsynaptic, but not presynaptic, NCAM expression controls synaptic strength in an activity-dependent manner by regulating the number of synapses [4]. A recent study has shown that repeated treatment with mor-

163 phine alters the expression levels of the polysialylated NCAM
 164 in the adult rat hippocampus [6]. Taken together, these findings
 165 raise the possibility that repeated treatment with morphine pro-
 166 motes the expression of NCAM and mGluR5 at the postsynaptic
 167 regions to increase the excitatory synaptic transmission in oppo-
 168 sition to excessive activation of inhibitory neurons in the dorsal
 169 horn. Although additional studies are needed to further demon-
 170 strate the effect of chronic morphine treatment on direct changes
 171 in excitatory or inhibitory synaptic transmission, the present data
 172 support the idea that repeated stimulation of μ -opioid receptors
 173 may initially cause the long-lasting suppression of the release of
 174 glutamate, and in turn may increase the expression of NCAM and
 175 mGluR5 at the postsynaptic regions in order to enhance the glu-
 176 tamate synaptic transmission. This phenomenon may be, at least
 177 in part, responsible for the suppression of the morphine-induced
 178 antinociception, which is called tolerance to spinal antinocicep-
 179 tion induced by morphine.

180 In conclusion, repeated *in vivo* treatment with morphine
 181 induced a significant increase in the expression of NCAM asso-
 182 ciated with the up-regulation of mGluR5 in the dorsal horn of
 183 mouse spinal cord. This may be linked to the development of
 184 morphine tolerance and the induction of neuronal plasticity by
 185 chronic morphine treatment.

186 Acknowledgments

187 This work was supported in part by grants from the Ministry
 188 of Health, Labour and Welfare, and the Ministry of Education,
 189 Culture, Sports, Science and Technology of Japan.

190 References

191 [1] F.J. Alvarez, R.M. Villalba, P.A. Carr, P. Grandes, P.M. Somohano,
 Differential distribution of metabotropic glutamate receptors 1a, 1b,

- and 5 in the rat spinal cord, *J. Comp. Neurol.* 422 (2000) 464–
 487. 192
 193
 [2] B. Bie, Z.Z. Pan, Increased glutamate synaptic transmission in the
 nucleus raphe magnus neurons from morphine-tolerant rats, *Mol. Pain*
 1 (2005) 7. 194
 195
 [3] M.M. Bradford, A rapid and sensitive method for the quantitation of
 microgram quantities of protein utilizing the principle of protein dye
 binding, *Anal. Biochem.* 72 (1976) 248–254. 196
 197
 [4] A. Dityatev, G. Dityateva, M. Schachner, Synaptic strength as a func-
 tion of post- versus presynaptic expression of the neural cell adhesion
 molecule NCAM, *Neuron* 26 (2000) 207–217. 198
 199
 [5] J.L. Hylden, G.L. Wilcox, Intrathecal morphine in mice: a new tech-
 nique, *Eur. J. Pharmacol.* 67 (1980) 313–316. 200
 201
 [6] L. Kahn, G. Alonso, E. Normand, O.J. Manzoni, Repeated morphine
 treatment alters polysialylated neural cell adhesion molecule, glutamate
 decarboxylase-67 expression and cell proliferation in the adult rat hip-
 pocampus, *Eur. J. Neurosci.* 21 (2005) 493–500. 202
 203
 [7] E. Kozela, A. Pile, P. Popik, Inhibitory effects of MPEP, an mGluR5
 antagonist, and memantine, an *N*-methyl-D-aspartate receptor antagonist,
 on morphine antinociceptive tolerance in mice, *Psychopharmacology* 165
 (2003) 245–251. 204
 205
 [8] M. Narita, M. Suzuki, M. Narita, K. Niikura, A. Nakamura, M. Miy-
 atake, T. Aoki, Y. Yajima, T. Suzuki, Involvement of spinal metabotropic
 glutamate receptor 5 in the development of tolerance to morphine-
 induced antinociception, *J. Neurochem.* 94 (2005) 1297–1305. 206
 207
 [9] M. Narita, M. Suzuki, M. Narita, Y. Yajima, R. Suzuki, S. Shioda, T.
 Suzuki, Neuronal protein kinase C γ -dependent proliferation and hyper-
 trophy of spinal cord astrocytes following repeated *in vivo* administration
 of morphine, *Eur. J. Neurosci.* 19 (2004) 479–484. 208
 209
 [10] M. Sheng, J.M. Kim, Postsynaptic signaling and plasticity mechanisms,
Science 289 (2002) 766–780. 210
 211
 [11] E.L. Smith, P.A. Smith, W.L. Dewey, R.R. Javed, Effects of mGlu1 and
 mGlu5 metabotropic glutamate antagonists to reverse morphine tolerance
 in mice, *Eur. J. Pharmacol.* 492 (2004) 137–142. 212
 213
 [12] K.A. Trujillo, H. Akil, Inhibition of morphine tolerance and depen-
 dence by the NMDA receptor antagonist MK-801, *Science* 251 (1991)
 85–87. 214
 215
 [13] P. Washbourne, A. Dityatev, P. Scheiffele, T. Biederer, J.A. Weiner,
 K.S. Christopherson, A. El-Husseini, Cell adhesion molecules in synapse
 formation, *J. Neurosci.* 24 (2004) 9244–9249. 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231

Available online at www.sciencedirect.com

SCIENCE @ DIRECT®

European Journal of Pharmacology xx (2006) xxx–xxx

www.elsevier.com/locate/ejphar

Short communication

Role of gap junction in the expression of morphine-induced antinociception

Masami Suzuki, Minoru Narita*, Atsushi Nakamura, Tsutomu Suzuki*

Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan

Received 22 December 2005; accepted 20 January 2006

Abstract

The present study was undertaken to investigate whether gap junctional communication could be involved in morphine-induced antinociceptive response using blockers of the gap junctional channel, carbenoxolone and Gap27. Intrathecal pretreatment with either carbenoxolone or Gap27 caused a dose-dependent attenuation of morphine-induced antinociception. Furthermore, the dose–response line for morphine-induced antinociception was shifted to the right by 2.53-fold following intrathecal treatment with carbenoxolone. These findings suggest that gap-junctional-dependent communication in the mouse spinal cord may play, at least in part, a role in the expression of morphine-induced antinociception.

© 2006 Published by Elsevier B.V.

Keywords: Morphine; Gap junction; Antinociception

1. Introduction

A gap junction is a unique channel that directly connects cells with the interior of other cells. A gap junction enables the intercellular diffusion of molecules with a molecular mass of up to 1 kDa, including ions, cAMP, inositol (1,4,5)-triphosphate (IP₃), ATP and small peptides (Giaume and Venance, 1998; Zonta et al., 2003). A gap junction is composed of a clustered hemichannel, called a connexon, which forms aqueous conduits that link the intracellular compartments of coupled cells. Each connexon consists of a hexameric arrangement of gap junction proteins called connexin (Kamerlings et al., 2001; Bennett et al., 2003). Connexin forms at least 20 gene family members that are expressed in many different cell types (Rash et al., 2001; Willecke et al., 2002). These channels can be gated in response to various stimuli, including changes in voltage and intracellular pH (Saez et al., 2003). In the central nervous system, gap-junction-mediated intercellular communication between glial cells has long been thought to contribute to tissue homeostasis in the brain. The homeostatic function includes the transport of nutrients from the bloodstream to neurons, ‘spatial buffering’ of K⁺ released into the extracellular space during neuronal exci-

tation and uptake and dissipation of glutamate through gap-junction channels among astrocytes (De Pina-Benabou et al., 2001).

The stimulation of μ -opioid receptor by morphine can regulate a number of signaling pathways, including inhibition of adenylate cyclase activity, activation of inwardly rectifying K⁺ channels and blockade of Ca²⁺ entry through voltage-dependent Ca²⁺ channels (Childers, 1991). We previously demonstrated that the endoplasmic IP₃ receptor-mediated intracellular signaling pathway is implicated in the expression of antinociceptive effect of morphine (Aoki et al., 2003). Therefore, the aim of the present study was to investigate whether the gap junctional channel in the spinal cord could be implicated in the expression of morphine-induced antinociception.

2. Materials and methods

The present study was conducted in accordance with the Guiding Principles for the Care and Use of Laboratory Animals, Hoshi University, as adopted by the Committee on Animal Research of Hoshi University, which is accredited by the Ministry of Education, Culture, Sports, Science and Technology of Japan. Male ICR mice (Tokyo Laboratory Animals Science Co., Ltd.) were used in the present study.

Morphine (Sankyo) and blockers of the gap junction, 3 β -hydroxy-11-oxoolean-12-en-30-oic acid 3-hemisuccinate

* Corresponding authors. Tel.: +81 3 5498 5628; fax: +81 3 5498 5831.

E-mail addresses: narita@hoshi.ac.jp (M. Narita), suzuki@hoshi.ac.jp (T. Suzuki).




Fig. 1. Effects of carbenoxolone on the antinociception produced by subcutaneous (s.c.) injection of morphine. Intrathecal (i.t.) pretreatment with saline and carbenoxolone was performed at 30 min before morphine injection. (A) Intrathecal pretreatment with carbenoxolone (0.03–1.00 nmol/mouse) attenuated the antinociception produced by morphine (10.0 mg/kg, s.c.) in a concentration-dependent manner. $***P < 0.001$; saline vs. 1.00 nmol carbenoxolone. (B) The dose–response curve for the antinociceptive effect of morphine in carbenoxolone-pretreated mice (closed circle, carbenoxolone; 1.00 nmol/mouse, ED_{50} : 12.0 (8.18–17.5) mg/kg, s.c.) was significantly shifted to the right compared to saline-pretreated mice (open circle, ED_{50} : 4.75 (2.91–7.73) mg/kg, s.c.). Antinociception was calculated as percentage of the maximum possible effect (% MPE) according to the following formula; % MPE = (test latency – pre-drug latency)/(cut-off time – pre-drug latency) \times 100. Each point represents the mean \pm S.E.M. of 8–16 mice.

and the latency to responses was measured both before and after drug administration. Antinociception was calculated as percentage of the maximum possible effect (% MPE) according to the following formula; % MPE = (test latency – pre-drug latency)/(cut-off time – pre-drug latency) \times 100. Antinociceptive response represents as the mean \pm S.E.M. of % MPE. The ED_{50} value was calculated by GraphPad Prism Programs version 3.0 (GraphPad Software Inc.). The statistical significance of differences between groups was assessed with one-way analysis of variance (ANOVA) followed by the Bonferroni/Dunn multiple comparison test.

3. Results

To investigate the role of gap junctional communication in morphine-induced antinociception, we examined the effects of blockers of the gap junctional channel, carbenoxolone and Gap27, on the μ -opioid receptor-mediated antinociceptive response using the hot-plate test. Intrathecal (i.t.) pretreatment with carbenoxolone (0.03–1.00 nmol/mouse) significantly attenuated the antinociceptive response produced by subcutaneous (s.c.) treatment with morphine (10.0 mg/kg) in a concentration-dependent manner ($***P < 0.001$; saline-pretreated mice vs. 1.00 nmol carbenoxolone-pretreated mice, Fig. 1A). Furthermore, the dose–response curve for the antinociceptive effects of morphine was significantly shifted to the right by 2.53-fold following i.t. pretreatment with carbenoxolone (1.00 nmol/mouse, Fig. 1B; $***P < 0.001$). Under these conditions, carbenoxolone at the doses used in the present study had no effects on the basal hot-plate latency after s.c. treatment with saline (data not shown). Like carbenoxolone, intrathecal pretreatment with Gap27 (3.00 and 10.0 nmol/mouse)




Fig. 2. Effect of Gap27 on the antinociception produced by s.c. injection of morphine. Intrathecal pretreatment with saline and Gap27 was performed at 30 min before morphine injection. Intrathecal pretreatment with Gap27 (3.00 and 10.0 nmol/mouse) attenuated the antinociceptive response produced by s.c. treatment with morphine in a concentration-dependent manner. $**P < 0.01$ and $***P < 0.001$ vs. saline-pretreated 5.00 mg/kg morphine group, $***P < 0.001$ vs. saline-pretreated 10.0 mg/kg morphine group. Antinociception was calculated as percentage of the maximum possible effect (% MPE) according to the following formula; % MPE = (test latency – pre-drug latency)/(cut-off time – pre-drug latency) \times 100. Each point represents the mean \pm S.E.M. of 8–16 mice.

(carbenoxolone: Sigma-Aldrich) and Gap27 (amino-acid sequence SRPTEKTIFII, TOCRIS), were dissolved in 0.9% sterile saline.

Intrathecal (i.t.) injection was performed as described by Hylden and Wilcox (1980) using a 25 μ l Hamilton syringe with a 30 gauge 1/2 in. needle. The injection volume was 4 μ l for i.t. injection.

The morphine-induced antinociceptive response was evaluated by recording the latency to paw licking or tapping in the hot-plate test (55 ± 0.5 $^{\circ}$ C). To prevent tissue damage, we established a 30 s cut-off time. The test was performed 30 min after morphine treatment. Each animal served as its own control,

103 significantly attenuated the antinociceptive response produced by
 104 s.c. treatment with morphine (5.00 and 10.0 mg/kg) in a
 105 concentration-dependent manner (** $P < 0.01$ and *** $P < 0.001$
 106 vs. saline-pretreated 5.00 mg/kg morphine group, *** $P < 0.001$
 107 vs. saline-pretreated 10.0 mg/kg morphine group, Fig. 2).

108 4. Discussion

109 The central nervous system is composed of a closely associated
 110 network of neurons and glial cells. For a long time, astrocytes
 111 were considered to be limited to the structural, trophic and
 112 metabolic support of neurons. Recent accumulating evidence
 113 suggests that glial cells display rapid electrical responses to
 114 neuronal activity via gap junctional channels, which can trigger
 115 the propagation of Ca^{2+} waves (Alvarez-Maubecin et al., 2000;
 116 Zonta et al., 2003). Ca^{2+} waves are mediated by the diffusion of
 117 IP_3 through gap junctions between cells and are also regulated by
 118 the release of ATP through hemichannels (De Pina-Benabou et al.,
 119 2001; Galarreta and Hestrin, 2001).

120 Carbenoxolone is a moderately lipophilic glycyrrhetic acid
 121 derivative that has been shown to act directly on gap junctions in
 122 brain and other tissues to reduce conductance by up to 80%
 123 (Rozenental et al., 2001). Furthermore, it has been reported that
 124 Gap27 peptides target the second extracellular loop of Cx40 and
 125 Cx37/Cx43, which interrupt direct intracellular coupling in a
 126 connexin-specific fashion without disrupting the structural
 127 integrity of gap junction plaques at points of intercellular contact
 128 (Chaytor et al., 1997, 1998). In the present study, we found that i.t.
 129 pretreatment with two different gap-junction blockers carbenox-
 130 olone and Gap27, which did not have any effects on the
 131 nociceptive threshold of the hot-plate response when injected
 132 alone, caused a dose-dependent attenuation of morphine-induced
 133 antinociception. Recent in vitro study using the purified
 134 astrocytes' primary culture shows that morphine failed to affect
 135 the junctional permeability determined by dye transfer technique
 136 (Mantz et al., 1993). Consistent with these results, we previously
 137 reported that morphine had no direct effect on astrocytic activation
 138 in purified astrocytes, whereas it caused astrocytic activation in
 139 neuron/glia co-cultures (Narita et al., 2005, in press). Taken
 140 together, these findings suggest that the gap junctional channel in
 141 the spinal cord might be affected by morphine though the
 142 stimulation of μ -opioid receptor in neurons. Although gap-
 143 junction blockers do not clearly distinguish the two pathways,
 144 hemichannels and coupling between cells, these findings provide
 145 novel evidence that gap-junction channels in the spinal cord may
 146 be, at least in part, implicated in the expression of morphine-
 147 induced antinociception.

148 Acknowledgments

149 This work was supported in part by grants from the Ministry
 150 of Health, Labour and Welfare, and the Ministry of Education,
 151 Culture, Sports, Science and Technology of Japan.

References

- 152
 153 Alvarez-Maubecin, V., Garcia-Hernandez, F., Williams, J.T., Van Bockstaele, E. 153
 154 J., 2000. Functional coupling between neurons and glia. *J. Neurosci.* 20, 154
 155 4091–4098. 155
 156 Aoki, T., Narita, M., Ohnishi, O., Mizuo, K., Narita, M., Yajima, Y., Suzuki, T., 156
 157 2003. Disruption of the type 1 inositol 1,4,5-trisphosphate receptor gene 157
 158 suppresses the morphine-induced antinociception in the mouse. *Neurosci.* 158
 159 *Letts.* 350, 69–72. 159
 160 Bennett, M.V., Contreras, J.E., Bukauskas, F.F., Saez, J.C., 2003. New roles for 160
 161 astrocytes: gap junction hemichannels have something to communicate. 161
 162 *Trends Neurosci.* 26, 610–617. 162
 163 Chaytor, A.T., Evans, W.H., Griffith, T.M., 1997. Peptides homologous to 163
 164 extracellular loop motifs of connexin 43 reversibly abolish rhythmic 164
 165 contractile activity in rabbit arteries. *J. Physiol.* 503, 99–110. 165
 166 Chaytor, A.T., Evans, W.H., Griffith, T.M., 1998. Central role of heterocellular 166
 167 gap junctional communication in endothelium-dependent relaxations of 167
 168 rabbit arteries. *J. Physiol.* 508, 561–573. 168
 169 Childers, S.R., 1991. Opioid receptor-coupled second messenger systems. *Life* 169
 170 *Sci.* 48, 1991–2003. 170
 171 De Pina-Benabou, M.H., Srinivas, M., Spray, D.C., Scemes, E., 2001. 171
 172 Calmodulin kinase pathway mediates the K^+ -induced increase in gap 172
 173 junctional communication between mouse spinal cord astrocytes. *J.* 173
 174 *Neurosci.* 21, 6635–6643. 174
 175 Galarreta, M., Hestrin, S., 2001. Electrical synapses between GABA-releasing 175
 176 interneurons. *Nat. Rev., Neurosci.* 2, 425–433. 176
 177 Giaume, C., Venance, L., 1998. Intercellular calcium signaling and gap 177
 178 junctional communication in astrocytes. *Glia* 24, 50–64. 178
 179 Hylden, J.L., Wilcox, G.L., 1980. Intrathecal morphine in mice: a new 179
 180 technique. *Eur. J. Pharmacol.* 67, 313–316. 180
 181 Kamermans, M., Fahrfort, I., Schultz, K., Janssen-Bienhold, U., Sjoerdsma, 181
 182 T., Weiler, R., 2001. Hemichannel-mediated inhibition in the outer retina. 182
 183 *Science* 292, 1178–1180. 183
 184 Mantz, J., Cordier, J., Giaume, C., 1993. Effect of general anesthetics on 184
 185 intracellular communications mediated by gap junctions between astrocytes 185
 186 in primary culture. *Anesthesiology* 78, 892–901. 186
 187 Narita, M., Miyatake, M., Shibasaki, M., Tsuda, M., Koizumi, S., Narita, M., 187
 188 Yajima, Y., Inoue, K., Suzuki, T., 2005. Long-lasting change in brain 188
 189 dynamics induced by methamphetamine: enhancement of protein kinase C- 189
 190 dependent astrocytic response and behavioral sensitization. *J. Neurochem.* 190
 191 93, 1383–1392. 191
 192 Narita, M., Miyatake, M., Narita, M., Shibasaki, M., Shindo, K., Nakamura, A., 192
 193 Kuzumaki, N., Nagumo, Y., Suzuki, T., in press. Direct evidence of 193
 194 astrocytic modulation in the development of rewarding effects induced by 194
 195 drugs of abuse. *Neuropsychopharmacology.* 195
 196 Rash, J.E., Yasumura, T., Dudek, F.E., Nagy, J.I., 2001. Cell-specific expression 196
 197 of connexins and evidence of restricted gap junctional coupling between 197
 198 glial cells and between neurons. *J. Neurosci.* 21, 1983–2000. 198
 199 Rozenental, R., Srinivas, M., Spray, D.C., 2001. How to close a gap junction 199
 200 channel: efficacies and potencies of uncoupling agents. In: Giaume, C. (Ed.), 200
 201 *Connexin Methods and Protocols*, pp. 447–476. Totowa, NJ. 201
 202 Saez, J.C., Berthoud, V.M., Branes, M.C., Martinez, A.D., Beyer, E.C., 2003. 202
 203 Plasma membrane channels formed by connexins: their regulation and 203
 204 functions. *Physiol. Rev.* 83, 1359–1400. 204
 205 Willecke, K., Eiberger, J., Degen, J., Eckardt, D., Romualdi, A., Guldenagel, M., 205
 206 Deutsch, U., Sohl, G., 2002. Structural and functional diversity of connexin 206
 207 genes in the mouse and human genome. *Biol. Chem.* 383, 725–737. 207
 208 Zonta, M., Angulo, M.C., Gobbo, S., Rosengarten, B., Hossmann, K.A., 208
 209 Pozzan, T., Carmignoto, G., 2003. Neuron-to-astrocyte signaling is central 209
 210 to the dynamic control of brain microcirculation. *Nat. Neurosci.* 6, 43–50. 210
 211

Available online at www.sciencedirect.com

SCIENCE @ DIRECT®

European Journal of Pharmacology xx (2006) xxx – xxx

www.elsevier.com/locate/ejphar

Short communication

Chronic morphine treatment increases the expression of vesicular glutamate transporter 1 in the mouse spinal cord

Masami Suzuki, Minoru Narita*, Michiko Narita, Tsutomu Suzuki

Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan

Received 7 November 2005; received in revised form 2 January 2006; accepted 20 January 2006

Abstract

Long-term exposure to morphine results in tolerance to morphine-induced antinociception. Here, we found that mice tolerant to morphine exhibited the significant increase in the protein levels of the vesicular glutamate transporter 1 and the synaptic vesicle-specific small G protein Rab3A, but not vesicular glutamate transporter 2 and vesicular γ -aminobutyric acid transporter. These findings suggest that repeated treatment with morphine enhances excitatory synaptic transmission in the spinal cord, and in turn suppresses the morphine-induced antinociception.

© 2006 Published by Elsevier B.V.

Keywords: Morphine; Tolerance; Vesicular glutamate transporter

1. Introduction

In the central nervous system, the normal function of neural networks depends on a delicate balance between excitatory and inhibitory synaptic inputs. Vesicular glutamate transporter 1 and 2 (VGLuT1 and VGLuT2) are known to underlie the transport of glutamate into excitatory vesicles in the glutamatergic nerve terminals, which influence the strength of excitatory transmission (Wilson et al., 2005). Vesicular γ -aminobutyric acid (GABA) transporter (VGAT) is highly concentrated in the nerve endings of GABA- and glycine-containing neurons (Chaudhry et al., 1998).

The administration of morphine directly into the spinal cord produces a powerful antinociception/analgesia, which is mediated by opioid receptors located in the marginal layer of the dorsal horn of the spinal cord. It has been proposed that morphine acts at μ -opioid receptors localized on C-fiber terminals, which inhibits neurotransmitter release by inactivating voltage-gated calcium channels (Aicher et al., 2000).

Long-term exposure to morphine results in tolerance to opioid-induced antinociception. It has been well established that

glutamate receptors are critical in the development and maintenance of opioid tolerance (Trujillo and Akil, 1991; Narita et al., 2005). Here, we determined the effect of repeated treatment with morphine on the expression of VGLuT1, VGLuT2 and VGAT in the mouse spinal cord.

2. Materials and methods

The present study was conducted in accordance with the Guiding Principles for the Care and Use of Laboratory Animals, Hoshi University, as adopted by the Committee on Animal Research of Hoshi University, which is accredited by the Ministry of Education, Culture, Sports, Science and Technology of Japan. Male ICR mice (Tokyo Laboratory Animals Science Co., Ltd.) weighing 25–28 g were used in the present study. The drugs used were morphine hydrochloride (Sankyo Co., Tokyo, Japan).

Groups of mice were repeatedly injected with morphine (10 mg/kg s.c.) and saline (10 ml/kg s.c.) once a day for 7 consecutive days. Twenty-four hours after the last injection, mice were sacrificed by decapitation. Their whole spinal cords were removed quickly and homogenized in ice-cold buffer (20 mM Tris-HCl, 2 mM EDTA, 0.5 mM EGTA, pH 7.5) containing protease inhibitors cocktail. The homogenate was centrifuged at 1000×g for 10 min and the supernatant was

* Corresponding author. Tel. +81 3 5498 5628; fax: +81 3 5498 5831.

E-mail addresses: narita@hoshi.ac.jp (M. Narita), suzuki@hoshi.ac.jp (T. Suzuki).

59 ultracentrifuged at 100,000×g for 30 min at 4 °C. The final
60 pellets were retained as the membranous fraction for Western
61 blotting at –80 °C until the assay. Total protein concentration in
62 each sample was determined by the Bradford assay. Sample
63 aliquots containing 10–20 µg total proteins were separated by
64 size on 5–20% sodium dodecyl sulfate-polyacrylamide gradient
65 gel and transferred to nitrocellulose membranes. The membrane
66 was incubated with primary antibody diluted in Tris-buffered
67 saline (TBS) [1:800 vesicular glutamate transporter 1 (VGluT1,
68 CHEMICON), 1:800 vesicular glutamate transporter 2 (VGluT2,
69 CHEMICON), 1:500 vesicular GABA transporter (VGAT, Syn-
70 aptic System), 1:1000 Rab3A (SANTA CRUZ), 1:1000 NR1
71 (SANTA CRUZ), 1:500 Glu1 receptor (Upstate)] containing 5%
72 nonfat dried milk. Immunoreactive bands were detected using
73 SuperSignal West Dura chemiluminescent kit (Pierce, Rockford,
74 IL, USA) and quantified using NIH Image. Statistical analyses
75 were performed using Student's *t* test.

76 3. Results

77 We assessed the effects of repeated treatment with morphine
78 on changes in levels of membrane-bound VGluT1, VGluT2 and

79 VGAT in the mouse spinal cord. Repeated s.c. treatment with
80 morphine once a day for 7 consecutive days produced a time-
81 dependent inhibition of the morphine-induced antinociception
82 (data not shown). The membranous fractions of the whole spinal
83 cords were prepared at 24 h after the last repeated injection of
84 saline and morphine. Western blots showed that protein levels
85 of membrane-bound VGluT1, but not VGluT2 and VGAT, in
86 the spinal cord were significantly increased by repeated treat-
87 ment with morphine compared to those in the saline-treated
88 mice (Fig. 1A, B, C: VGluT1; 148.3±11.1% of control, $P<0.01$
89 vs. chronic saline-treated group). In contrast, the level of
90 membrane-bound VGluT1 was significantly decreased by acute
91 in vivo treatment with morphine (Fig. 1G: VGluT1; 69.4±2.5%
92 of control, $P<0.001$ vs. acute saline-treated group). In addition,
93 mice that were tolerant to morphine exhibited a robust increase
94 in the protein level of the small GTP-binding protein Rab3A,
95 which plays a role in the recruitment of synaptic vesicles for
96 exocytosis (Fig. 1D: 228.3±18.5% of control, $P<0.001$ vs.
97 saline-treated group). However, the protein level of Rab3A in
98 membranes of the mouse spinal cord was not affected by a
99 single injection of morphine (Fig. 1H). Under these conditions,
100 protein levels of membrane-bound NR1 subunit, which is the




Fig. 1. (A–F) Change in protein levels of membrane-bound VGluT1 (A), VGluT2 (B), VGAT (C), Rab3A (D), NR1 (E) and Glu1 receptor (F) in the whole spinal cord following repeated treatment with morphine. Groups of mice were injected with saline or morphine (10 mg/kg, s.c.) once a day for 7 consecutive days. The membranous fractions were prepared at 24 h after the last injection. (G, H) Change in protein levels of membrane-bound VGluT1 (G) and Rab3A (H) in the whole spinal cord following a single injection of morphine. The samples were prepared at 30 min after s.c. injection of morphine. Upper: Representative Western blots of VGluT1, VGluT2, VGAT, Rab3A, NR1 and Glu1 receptor. Lower: Changes in immunoreactivities for VGluT1, VGluT2, VGAT, Rab3A, NR1 and Glu1 receptor in membranous fractions of whole spinal cords obtained from saline- or morphine-treated mice. Each column represents the mean with S.E.M. of 3 independent samples. ** $P<0.01$, *** $P<0.001$ vs. saline-treated mice.

101 obligatory subunit of functional NMDA receptor, and Glu1
102 receptor subunit, which appears to be expressed at the majority
103 of synapses containing AMPA receptors, in the spinal cord were
104 not altered by repeated treatment with morphine (Fig. 1E, F).

105 4. Discussion

106 The key finding in the present study was that a single
107 injection of morphine caused a significant decrease of levels of
108 VGluT1 in the mouse spinal cord, whereas repeated in vivo
109 treatment with morphine induced a significant increase in the
110 protein levels of membrane-bounded VGluT1 and Rab3A. In
111 contrast, repeated treatment with morphine showed no change
112 in protein levels of membranous fraction of VGluT2, VGAT,
113 NR1 subunit and Glu1 receptor subunit in the mouse spinal
114 cord. Rab3A has been proposed to participate in the docking of
115 synaptic vesicles to appropriate sites of the presynaptic
116 membrane by interacting with presynaptic effectors localized
117 at active zones (Geppert et al., 1994). Furthermore, it is
118 considerable that the expression of VGluT1 directly regulates
119 the extent of glutamate release, providing a concise presynaptic
120 mechanism for controlling the quantal efficacy of excitatory
121 transmission during synaptic refinement and plasticity (Wilson
122 et al., 2005). In our preliminary, we found that high K^+ -induced
123 glutamate release in spinal neuron/glia co-cultures was largely
124 increased following chronic morphine treatment compared with
125 that of the control (data not shown). It was previously reported
126 that the distribution pattern of the immunoreactivity for VGluT1
127 was different from that of VGluT2. The immunoreactivity for
128 VGluT1 was found to be moderate to intense in the inner part of
129 the substantia gelatinosa (laminae II) and the deeper part of the
130 magnocellular layer (laminae III), whereas the immunoreactiv-
131 ity for VGluT2 was most intense in the marginal layer (laminae
132 I) and the outer part of the substantia gelatinosa (Li et al., 2003).
133 We previously reported that mice tolerated to morphine
134 exhibited the increase in immunoreactivities for mGluR5 and
135 protein kinase $C\gamma$ (PKC γ) with their expanding distribution in
136 the substantia gelatinosa of the spinal dorsal horn after repeated
137 treatment with morphine (Narita et al., 2004, 2005). Taken
138 together, these findings raise the possibility that repeated
139 treatment with morphine promotes the expression of VGluT1 at
140 the presynaptic regions in the substantia gelatinosa and the

magnocellular layer in the dorsal horn to increase the excitatory
synaptic transmission in opposition to excessive activation of
inhibitory neurons in the marginal layer of the dorsal horn of the
spinal cord. Although additional studies are necessary to
demonstrate the effect of chronic morphine treatment on direct
changes in excitatory or inhibitory synaptic transmission, this
phenomenon may be, at least in part, responsible for the
suppression of the morphine-induced antinociception, which
could be eventually called tolerance to spinal antinociception
induced by morphine.

Acknowledgments

This work was supported in part by grants from the Ministry
of Health, Labour and Welfare, and the Ministry of Education,
Culture, Sports, Science and Technology of Japan.

References

- Aicher, S.A., Sharma, S., Cheng, P.Y., Liu-Chen, L.Y., Pickel, V.M., 2000. Dual
ultrastructural localization of μ -opioid receptors and substance P in the
dorsal horn. *Synapse* 36, 12–20.
- Chaudhry, F.A., Reimer, R.J., Belloccchio, E.E., Danbolt, N.C., Osen, K.K.,
Edwards, R.H., Storm-Mathisen, J., 1998. The vesicular GABA transporter,
VGAT, localizes to synaptic vesicles in sets of glycinergic as well as
GABAergic neurons. *J. Neurosci.* 18, 9733–9750.
- Geppert, M., Bolshakov, V.Y., Siegelbaum, S.A., Takei, K., De Camilli, P.,
Hammer, R.E., Sudhof, T.C., 1994. The role of Rab3A in neurotransmitter
release. *Nature* 369, 493–497.
- Li, J.L., Fujiyama, F., Kaneko, T., Mizuno, N., 2003. Expression of vesicular
glutamate transporters, VGluT1 and VGluT2, in axon terminals of
nociceptive primary afferent fibers in the superficial layers of the medullary
and spinal dorsal horns of the rat. *J. Comp. Neurol.* 457, 236–249.
- Narita, M., Suzuki, M., Narita, M., Yajima, Y., Suzuki, R., Shioda, S., Suzuki,
T., 2004. Neuronal protein kinase $C\gamma$ -dependent proliferation and
hypertrophy of spinal cord astrocytes following repeated in vivo
administration of morphine. *Eur. J. Neurosci.* 19, 479–484.
- Narita, M., Suzuki, M., Narita, M., Niikura, K., Nakamura, A., Miyatake, M.,
Aoki, T., Yajima, Y., Suzuki, T., 2005. Involvement of spinal metabotropic
glutamate receptor 5 in the development of tolerance to morphine-induced
antinociception. *J. Neurochem.* 94, 1297–1305.
- Trujillo, K.A., Akil, H., 1991. Inhibition of morphine tolerance and dependence
by the NMDA receptor antagonist MK-801. *Science* 251, 85–87.
- Wilson, N.R., Kang, J., Hueske, E.V., Leung, T., Varoqui, H., Murnick, J.G.,
Erickson, J.D., Liu, G., 2005. Presynaptic regulation of quantal size by the
vesicular glutamate transporter VGLUT1. *J. Neurosci.* 25, 6221–6234.

184